Smart combo therapy aims to wipe out hidden myeloma cells
NCT ID NCT06353022
First seen Mar 17, 2026 · Last updated May 08, 2026 · Updated 10 times
Summary
This study tests whether adding T-cell redirecting drugs (teclistamab and talquetamab) to standard therapy can eliminate remaining cancer cells in people with newly diagnosed multiple myeloma. About 103 adults under 66 will receive one of two drug combinations based on their minimal residual disease (MRD) status. The goal is to achieve and maintain a deep remission, but ongoing treatment is needed, so this is a disease control strategy, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHP Hôpital La Pitié Salpétrière
Paris, 75013, France
-
APHP Hôpital Saint-Antoine
Paris, 75012, France
-
CH Lyon Sud
Lyon, 69495, France
-
CH de la Côte Basque
Bayonne, 64109, France
-
CHRU DIjon
Dijon, 21000, France
-
CHRU LILLE - Hôpital Claude Huriez
Lille, 59037, France
-
CHRU Nancy - Hôpitaux de Brabois
Vandœuvre-lès-Nancy, 54511, France
-
CHRU Rennes - Hôpital de Pontchaillou
Rennes, 35033, France
-
CHU BORDEAUX - Hôpital du Haut Lévêque
Pessac, 33604, France
-
CHU Caen
Caen, 14033, France
-
CHU Limoges
Limoges, 87000, France
-
CHU Montpellier
Montpellier, 34295, France
-
CHU Poitiers
Poitiers, 86000, France
-
CHU Toulouse
Toulouse, 31059, France
-
CHU Tours Hôpital Bretonneau
Tours, 37044, France
-
CHU de Nantes
Nantes, 44093, France
-
CHU de Strasbourg (HUS)
Strasbourg, 67200, France
-
Chd Vendee
La Roche-sur-Yon, 85925, France
-
IPC Marseille Institut Paoli Calmettes
Marseille, 13009, France
Conditions
Explore the condition pages connected to this study.